Official Title
Severe COVID-19 Infection in Children Presenting to Emergency Departments in Israel and England: A Prospective Multicenter Study
Brief Summary

Even though the COVID-19 pandemic is no longer at its peak, the threat still lingers.Engaging in prospective surveillance studies will enable us to monitor the disease andprepare for any potential resurgence. COVID-19 surveillance studies are essential toolsfor policymakers to make informed decisions, allocate resources, and develop strategiesto control the spread of the virus and protect public health.The objective of this surveillance study is to prospectively assess in-hospital severemorbidity related to COVID-19 infection in children who present to the PediatricEmergency Department (ED).A prospective multicenter study will be conducted across eight EDs in Israel and five EDsin the United Kingdom. The study population will include children aged 16 years oryounger with a severe acute COVID-19 infection. Confirmation of acute COVID-19 infectionwill be based on polymerase chain reaction nasopharyngeal swab testing. The study willalso include patients diagnosed with multisystem inflammatory syndrome in children(MIS-C), as defined by the CDC.

Detailed Description

Not Provided

Recruiting
COVID-19
Inflammatory Response

Diagnostic Test: Nasopharyngeal swab sampling for COVID-19

The healthcare provider will gently insert the swab a short distance (1-1.5 cm for young
children) into one nostril, reaching the back of the nasal cavity. The swab will then be
gently rotated and rubbed for a few seconds to collect a sample of mucus. The same
process may be repeated in the other nostril.

Eligibility Criteria

Inclusion Criteria:

1. SACI

Patients aged 16 years or younger with a positive COVID-19 PCR nasopharyngeal swab
testing or bronchoalveolar sample who meet the definition of SACI:

- Receive oxygen via low-flow nasal cannula or oxygen mask, high-flow nasal
cannula, bilevel or continuous positive airway pressure machine, mechanical
ventilation, or extracorporeal membrane oxygenation (ECMO) Or

- Admitted to ICU

2. MIS-C Patients aged 16 years or younger diagnosed with MIS-C

Eligibility Gender
All
Eligibility Age
Minimum: 0 Years ~ Maximum: 16 Years
Countries
Israel
Locations

Haemek Medical Center
Afula, Israel

Soroka Medical Center
Be'er Sheva, Israel

Hadassah Medical Center
Jerusalem, Israel

Shaare Zedek Medical Center
Jerusalem, Israel

Meir Medical Center
Kfar Saba, Israel

Sheba Medical Center
Tel HaShomer, Israel

Contacts

Itai Shavit, MD
00 972 50 2063239
shavit1@hadassah.org.il

Hadas Lamberg, PhD
00 972 2 6777572
lhadas@hadassah.org.il

Not Provided

London North West Healthcare NHS Trust
NCT Number
MeSH Terms
COVID-19